Overall, PAC alleviates hepatic steatosis in NAFLD by enhancing FGF21 expression, activating the FGF21/FGFR1 signaling axis, and inhibiting p38MAPK activation. This evidence concerns the gene FGFR1 and metabolic dysfunction-associated steatotic liver disease.